Combination of axitinib and dasatinib for anti-cancer activities in two prostate cancer cell lines

Authors

  • Nai-Xiong Peng Department of Urology, Zhujiang Hospital Southern Medical University, Guangzhou, Guangdong 510280
  • Chun-Xiao Liu Department of Urology, Zhujiang Hospital Southern Medical University, Guangzhou, Guangdong 510280 http://orcid.org/0000-0002-5577-7883
  • Xi-Sheng Wang Department of Urology, The Longhua New District Central Hospital, Shenzhen, Guangdong 518110
  • Ze-Jian Zhang Department of Urology, The Longhua New District Central Hospital, Shenzhen, Guangdong 518110
  • Su-Cai Liao Department of Urology, The Longhua New District Central Hospital, Shenzhen, Guangdong 518110

DOI:

https://doi.org/10.3329/bjp.v11i1.24149

Keywords:

Anti-cancer, Axitinib, Dasatinib, Prostate cancer cell line

Abstract

Prostate cancer is the major cause of cancer-related deaths worldwide in men. There are new treatment methods and drugs are being developed with promising results in two of the prostate cancer cell lines (PPC-1 and TSU-Pr1). These two cells were treated with 20 uM of axitinib combined with dasatinib for 6-72 hours. The cell viability assessed by the cytotoxicity assay. Various regulatory genes such as c-KIT, cell cycle and apoptosis and angiogenic factors were also studied. The enzyme activity of apoptosis effector caspase-3 was colorimetrically determined. Axitinib and dasatinib combination lowered the survival rate of PPC-1 cells but enhanced the survival rate of TSU-Pr1 cells. The protein expression levels in apoptosis and angiogenesis factors were also found to be in contrast between the two cell lines. PPC-1 and TSU-Pr1 cells displayed a different response to axitinib with dasatinib, which explains different expression levels of regulators of cell-cycle, apoptosis and angiogenesis.

Downloads

Download data is not yet available.
Abstract
1298
Download
590 Read
645

Published

2015-12-25

How to Cite

Peng, N.-X., C.-X. Liu, X.-S. Wang, Z.-J. Zhang, and S.-C. Liao. “Combination of Axitinib and Dasatinib for Anti-Cancer Activities in Two Prostate Cancer Cell Lines”. Bangladesh Journal of Pharmacology, vol. 11, no. 1, Dec. 2015, pp. 130-7, doi:10.3329/bjp.v11i1.24149.

Issue

Section

Research Articles